pharmaphorum5d
Merck and Moderna's mRNA cancer vaccine aces its first efficacy trial
The trial compared Moderna's MRNA-4157/V940 vaccine given alongside Merck & Co's cancer immunotherapy Keytruda (pembrolizumab) to Keytruda alone in patients with the skin cancer melanoma.
Hosted on MSN1mon
Moderna spikes as Oracle’s Larry Ellison touts AI-driven mRNA vaccines
The Cambridge, Massachusetts-based biotech's personalized cancer vaccine mRNA-4157, developed with Merck (MRK), is currently in late-stage development targeting patients with skin cancer melanoma.
pharmaphorum1y
Merck, Moderna cue up phase 3 trials for mRNA cancer shot
The two partners have presented updated results from the phase 2b KEYNOTE-942 trial of the mRNA-4157 vaccine, given in combination with Merck’s PD-1 inhibitor Keytruda (pembrolizumab ...
Melanoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
Melanoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or ...
Yahoo Finance3d
Moderna, Inc. (MRNA)
a pivotal Phase 3 randomized clinical trial evaluating V940 (mRNA-4157), an investigational individualized neoantigen therapy (INT), in combination with KEYTRUDA® (pembrolizumab), Merck’s anti ...